Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
JACC. Heart Failure|November 9, 2023
Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension StudyPablo Garcia-Pavia, Marla B Sultan, Balarama Gundapaneni, et al.
Haematologica|May 30, 2013
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvementShira Dinner, Wesley Witteles, Anosheh Afghahi, et al.
JACC. Advances|October 7, 2024
Impact of Case and Control Selection on Training Artificial Intelligence Screening of Cardiac AmyloidosisAmey Vrudhula, Lily Stern, Paul C Cheng, et al.
Molecular Therapy. Nucleic Acids|July 21, 2025
Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosisMartha Grogan, Farooq H Sheikh, Brett W Sperry, et al.
Journal of Hospital Medicine|March 3, 2020
Portable Ultrasound Device Usage and Learning Outcomes Among Internal Medicine Trainees: A Parallel-Group Randomized TrialAndre Kumar, Yingjie Weng, Libo Wang, et al.
The American Journal of Cardiology|August 29, 2017
Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry)Mirela Tuzovic, Yukari Kobayashi, Matthew Wheeler, et al.
JACC. Advances|June 24, 2025
Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-BJohn L Berk, Olivier Lairez, Pedro Schwartzmann, et al.
EJNMMI Research|July 26, 2018
18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid depositionLucia Baratto, Sonya Youngju Park, Negin Hatami, et al.
British Journal of Haematology|February 26, 2013
The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosisShira Dinner, Wesley Witteles, Ronald Witteles, et al.
JACC. Cardiooncology|September 6, 2024
Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid CardiomyopathyRonald Witteles, John L Jefferies, Suraj Kapa, et al.
Pageof 5